Masatugu Tsji received PhD in Economics from Stanford University in 1976. He is currently working as a professor at Kobe international University. His serves include visiting professors of Carnegie Mellon University. US and National Cheng Kung University, Taiwan; Board of Director, International telecommunication Society; Editorial Board. Journal of International Society of Telemedicine and Health, and Smart homecare Technology and telehealth; Coordinator of e-Health Economics, ISfTeH. His current research focuses on economic evaluation of telemedicine and e-Health. He has been Japanese Government and local governments for implementing telemedicine projects.
Minoru Yamakado is Dean and Professor, Department of Nursing, Ashikaga University and Special Adviser, Health Care Center, Mitsui Memorial Hospital. He received his Medical Doctor’s degree from Department of Medicine, University of Gunma in 1972. After he was a Resident of Mitsui Memorial Hospital, 1972~1974, he was a Medical Staff, Department of Internal Medicine, Mitsui Memorial Hospital, 1974~1978 and a Medical Staff, Department of Internal Medicine, University of Tokyo School Of Medicine, 1978~1981. After receiving his PhD degree from University of Tokyo in 1981, he joined Professor PJ Mulrow’s Laboratory of Hypertension at Medical College of Toledo, Ohio, USA as a research fellow, 1981~1983. After returning Japan, he was a Chief Staff of Center for Kidney Diseases, 1983~1991, Director, Department of Preventive Medicine , 1991~1994, Director, Health Screening Center, 1994~2012, and Special Adviser of Health Screening Center of Mitsui Memorial Hospital from 2012. He is appointed Dean and Professor, Department of Nursing of Ashikaga University from 2014. His specialty is preventive medicine and hypertension. His board certifications are Fellows of Japanese Society of Internal Medicine, Councilor of Japanese Society of Anti-aging Society, Honorable Councilor of Japanese Society of Nephrology, Japanese Society of Endocrinology, Japanese Society of Atherosclerosis, Japanese Society of Obesity and Members of Internal Society of Nephrology and American Society of Hypertension.
Acting Assistant Dean, Professor in College of Nursing, University of Saskatchewan. Research Team Member, Principal Investigator on numerous and Co-principal Investigator on multiple research projects. Adjunct appointment at Prince Albert Parkland Health Region (2009-2010). Associate Dean, Executive Team, University of Saskatchewan (2005-2010). Saskatchewan Health Research Foundation, “Strengthening Inter-Professional Ethics Education Practices of Nursing and Social Work Professionals in Saskatchewan: Deepening Understandings of Ethical Issues and Early Indicators”.
Soheyl Asadsangabi studied Midwifery in Iran and completed her Doctoral study (DNP) as a midwife from Vanderbilt University. She has been practicing midwifery since 2004 in private and academic settings. As a woman from another culture and a clinician who provides care for a diverse population her focus is on cross cultural women’s health care. She is currently an Assistant Professor at Vanderbilt School of Medicine.
Dr. John Burd has completed Ph.D. in Biochemistry from the University of Wisconsin, and He has been developing medical products for over 40 years. He has a passion to help people with diabetes to better health and longer lives. John Burd proudest moment was the founding of DexCom, now the leader in continuous glucose monitoring with over 1 million users worldwide.
The researcher completed a master's degree from the National Taipei University of Nursing and Health Sciences in 2011. He currently serves as a head-nursing in the National Cheng Kung University Hospital. He has published one paper in the journal and participated in five academic posters.
Dedy Arisjulyanto is one of the postgraduate students of Public Health Universitas Gadjah Mada, he has expertise in overcoming non communicable diseases with complementary therapy and adolescent reproductive health , this research was conducted directly in the community and analyzed it by quantitative way and various theoretical references, this research became a very good recommendation in overcoming hypertension problem in world
Takeshi Oki has completed his Ph.D. from Okayama University School of Medicine, Okayama, Japan and M.D. from Chiba University Graduate School of Medicine, Chiba, Japan. He has been certified on the board of Japanese Society of Internal Medicine, the board of Japanese Society of Neurology, the board of Japan Stroke Society, on the board of Japan Society for Dementia Research. He has opened Trinity Neurology Clinic after ten years working at local neurology clinic. He is now the director of Trinity Neurology Clinic, the clinical professor of Chiba University and part time instructor of Toho University.
Dr. Monroe has completed her PhD at Texas Woman’s University. As a previous staff-nurse, she has worked in the field of cardiovascular nursing since 1991. She has worked as nurse educator since 2007. Currently, she is a clinical assistant professor at PVAMU-CON. She has published previously on this same topic; and serves on the editorial board of a nursing journal.
Emil Mukhamejanov - doctor of medical sciences, professor. In 1964-1972, I worked in the
Institute of Physiology, responsible for the regulation of muscle contraction. In 1974-1991, I
worked in the Institute of nutrition, responsible for the regulation of energy metabolism and
metabolic diseases. Developed metabolic model of balanced diet coupled with effects of toxic
compounds, physical activity and dietary factors. Has developed specialized nutrition products for
athletes and for the prevention and treatment of metabolic diseases. Currently working in the
Scientific Center of anti-infective disorders, develop approaches of reducing the negative impact of
drugs. I participate in a grant (JSC National Medical University named after S.Asfendiarov) for the
study of polymorphism in diabetes mellitus. I am a scientific consultant at International Institute of
Rosy Cárdenas is finishing her PhD from Universidad Nacional de Colombia. She is the leader of Clinical Movement Laboratory, of the School of Medicine and Health Sciences at Universidad del Rosario. She researchs in the Rehabilitation Science Research Group at Universidad del Rosario and in the Tisssue and Organ Mechanobiology Research Group at Universidad Nacional de Colombia. She has published 8 papers in reputed journals.
Jama Lambert is a graduate of the University of Oregon. She has spent thirteen years under the mentorship of Aristo Vojdani, renowned microbiologist and immmunologist. She has co-authored multiple peer-reviewed publications, as well as six book chapters and has edited medical books. She has presented original research at the last two International Congresses on Autoimmunity and has lectured, or presented posters, at medical conferences. She is currently the Vice President, Education at Cyrex Laboratories, LLC and is working towards a PhD in Public Health and Nutrition.
Bernard P. Roques earned degrees in pharmacy and pharmacology at René Descartes University, Paris, France, and a Ph.D in Physical Chemistry at the Ecole Polytechnique, where he was Assistant Professor 1970-1976, and then Professor of Pharmacochemistry at René Descartes University and Director of the Departement de Pharmacochimie Moléculaire et Structurale associated with the Centre National de la Recherche Scientifique (CNRS) and Institut National de la Santé et de la Recherche Médicale (INSERM) from 1976-2001. During this period he designed Stagid® the first antidiabetic agent with long duration of action still on the international market. His laboratory designed the first DNA polyintercalators, in addition to discovering potent and selective agonists of the -opioid receptor and subsequently demonstrating their potential interest as antidepressants. In 1980, he developed selective inhibitors of enkephalin-inactivating enzymes, one of them Tiorphan® being on the market as antidiarrheal agent very convenient for infants and proposed the concept of dual inhibitors DENKisfor the complete protection of enkephalins and its extension to metallopeptidases involved in cardiovascular diseases. B.P. Roques is author of more than 500 publications and 30 patents. At present, his laboratory specializes in the development of inhibitors of the zinc metallopeptidases involved in peptide metabolism, which are of potential interest in analgesia, cardiovascular field, neurodegenerative processes, migraine, glaucoma and cancer. Among international awards, B.P. Roques has received the Charles Mentzer Prize from the Medicinal Chemistry Society (1994), the INSERM Academy of Sciences Award (1994), the G. Witter/V. Grignard Prize from the Gesellschaft Deutscher Chemiker (1996), the Galien Prize of Pharmaceutical Research (1977) and the Rudinger Award from the European Peptide Society (2000), the Founder’s Award from the International Narcotic Research Committee. He is member of the French and European Academy of Sciences. Now Scientific Director of the start-up company Pharmaleads founded by him in 2001, B.P. Roques has participated to the development and commercialization of : i) new methods for the detection of very low concentration of botulinum toxin usefull in bioterrorism oversight and in treatment of neurological diseases and wrinkles attenuation; ii) Fluofast, a universal substrate library for proteases and phosphatases. Two DENKIs, PL37 and PL265 are now I clinical trials and PL37 now found efficient in phase 2 to treat neuropathic pain and activation, retina pain and migraine.